Edwards Lifesciences (NYSE:EW) Announces Quarterly Earnings Results

Edwards Lifesciences (NYSE:EW) announced its earnings results on Tuesday. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04, Zacks reports. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences updated its FY 2025 guidance to 2.400-2.500 EPS and its Q1 2025 guidance to 0.580-0.640 EPS.

Edwards Lifesciences Stock Down 0.2 %

Shares of NYSE:EW opened at $70.95 on Wednesday. The firm has a market capitalization of $41.85 billion, a PE ratio of 10.24, a price-to-earnings-growth ratio of 3.64 and a beta of 1.10. Edwards Lifesciences has a 1 year low of $58.93 and a 1 year high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm’s 50-day moving average is $72.47 and its two-hundred day moving average is $69.32.

Insider Activity

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of the stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now owns 23,189 shares of the company’s stock, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on EW shares. The Goldman Sachs Group lifted their price target on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. Citigroup upped their target price on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price target for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Wolfe Research cut shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price objective for the company. in a research note on Thursday, January 16th. Finally, Barclays raised their target price on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a research note on Monday, December 2nd. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $79.43.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.